Literature DB >> 17031720

1173C>T polymorphism in VKORC1 modulates the required warfarin dose.

K Kosaki1, C Yamaghishi, R Sato, H Semejima, H Fuijita, K Tamura, K Maeyama, H Yamagishi, A Sugaya, H Dodo, Y Tanigawara, T Takahashi.   

Abstract

The response to warfarin is highly variable among individuals and such variability is likely to have some genetic basis. We evaluted the effect of VKORC1 polymorphisms on warfarin response among Japanese, taking advantage of its unique population structure in which CYP2C9 *2 and *3 alleles are relatively rare. Thirty-one patients (12-34 years old; median, 22) on warfarin were recruited from a pediatric cardiology clinic. Genotyping of the C>T polymorphism at position 1173 in intron 1 of VKORC1 revealed that 26 patients (84%) were T/T homozygotes at nucleotide 1173, whereas 5 (16%) were C/T heterozygotes. Complete linkage disequilibrium was observed between the 1173C > T polymorphism and another polymorphism, the 3730G > A, in the 3' untranslated region. The C/T heterozyogtes at the 1173C > T polymorphism tended to require more warfarin than the T/T homozygotes, when adjusted for international normalized ratio (p = 0.003). Both the 1173C > T polymorphism and the 3730G > A polymorphism are likely to be inert from a functional standpoint. Rather, based on the complete linkage disequilibrium between 1173C > T and 3730G > A polymorphisms, we suspect that the actual change that defines the relative resistance to warfarin may be present in the proximity of these two polymorphisms.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17031720     DOI: 10.1007/s00246-005-1150-x

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN: 0172-0643            Impact factor:   1.655


  14 in total

Review 1.  Pharmacogenetics and adverse drug reactions.

Authors:  U A Meyer
Journal:  Lancet       Date:  2000-11-11       Impact factor: 79.321

2.  Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients.

Authors:  Harumi Takahashi; Grant R Wilkinson; Yoseph Caraco; Mordechai Muszkat; Richard B Kim; Toshitaka Kashima; Sosuke Kimura; Hirotoshi Echizen
Journal:  Clin Pharmacol Ther       Date:  2003-03       Impact factor: 6.875

3.  Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9.

Authors:  A E Rettie; L C Wienkers; F J Gonzalez; W F Trager; K R Korzekwa
Journal:  Pharmacogenetics       Date:  1994-02

4.  Genetic association between sensitivity to warfarin and expression of CYP2C9*3.

Authors:  D J Steward; R L Haining; K R Henne; G Davis; T H Rushmore; W F Trager; A E Rettie
Journal:  Pharmacogenetics       Date:  1997-10

5.  Pharmacodynamic resistance to warfarin associated with a Val66Met substitution in vitamin K epoxide reductase complex subunit 1.

Authors:  Dominic J Harrington; Sarah Underwood; Colin Morse; Martin J Shearer; Edward G D Tuddenham; Andrew D Mumford
Journal:  Thromb Haemost       Date:  2005-01       Impact factor: 5.249

6.  Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment.

Authors:  J Taube; D Halsall; T Baglin
Journal:  Blood       Date:  2000-09-01       Impact factor: 22.113

7.  A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin.

Authors:  Giovanna D'Andrea; Rosa Lucia D'Ambrosio; Pasquale Di Perna; Massimiliano Chetta; Rosa Santacroce; Vincenzo Brancaccio; Elvira Grandone; Maurizio Margaglione
Journal:  Blood       Date:  2004-09-09       Impact factor: 22.113

8.  The risk for and severity of bleeding complications in elderly patients treated with warfarin. The National Consortium of Anticoagulation Clinics.

Authors:  S D Fihn; C M Callahan; D C Martin; M B McDonell; J G Henikoff; R H White
Journal:  Ann Intern Med       Date:  1996-06-01       Impact factor: 25.391

9.  Factors affecting the maintenance dose of warfarin.

Authors:  A H James; R P Britt; C L Raskino; S G Thompson
Journal:  J Clin Pathol       Date:  1992-08       Impact factor: 3.411

10.  Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2.

Authors:  Simone Rost; Andreas Fregin; Vytautas Ivaskevicius; Ernst Conzelmann; Konstanze Hörtnagel; Hans-Joachim Pelz; Knut Lappegard; Erhard Seifried; Inge Scharrer; Edward G D Tuddenham; Clemens R Müller; Tim M Strom; Johannes Oldenburg
Journal:  Nature       Date:  2004-02-05       Impact factor: 49.962

View more
  13 in total

1.  Oral anticoagulation and VKORC1 polymorphism in patients with a mechanical heart prosthesis: a 6-year follow-up.

Authors:  Carlo Giansante; Nicola Fiotti; Nicola Altamura; Paola Pitacco; Lara Consoloni; Sabino Scardi; Carmine Mazzone; Gabriele Grassi; Claudio Pandullo; Andrea Di Lenarda
Journal:  J Thromb Thrombolysis       Date:  2012-11       Impact factor: 2.300

Review 2.  Clinical applications of pharmacogenomics guided warfarin dosing.

Authors:  Pramod Mahajan; Kristin S Meyer; Geoffrey C Wall; Heidi J Price
Journal:  Int J Clin Pharm       Date:  2010-11-04

3.  Evaluation of the effects of ontogenetic or maturation functions and chronic heart failure on the model analysis for the dose-response relationship of warfarin in Japanese children.

Authors:  Rika Tamura; Nao Watanabe; Saki Nakamura; Naoki Yoshimura; Sayaka Ozawa; Keiichi Hirono; Fukiko Ichida; Masato Taguchi
Journal:  Eur J Clin Pharmacol       Date:  2019-03-08       Impact factor: 2.953

4.  Vitamin K antagonists in children with heart disease: height and VKORC1 genotype are the main determinants of the warfarin dose requirement.

Authors:  Caroline Moreau; Fanny Bajolle; Virginie Siguret; Dominique Lasne; Jean-Louis Golmard; Caroline Elie; Philippe Beaune; Radhia Cheurfi; Damien Bonnet; Marie-Anne Loriot
Journal:  Blood       Date:  2011-11-30       Impact factor: 22.113

Review 5.  Clinical applications of pharmacogenomics guided warfarin dosing.

Authors:  Pramod Mahajan; Kristin S Meyer; Geoffrey C Wall; Heidi J Price
Journal:  Int J Clin Pharm       Date:  2011-02-04

Review 6.  Pharmacokinetics and pharmacodynamics of anticoagulants in paediatric patients.

Authors:  Donald L Yee; Sarah H O'Brien; Guy Young
Journal:  Clin Pharmacokinet       Date:  2013-11       Impact factor: 6.447

7.  Problems in anticoagulation of a patient with antibiotic treatment for endocarditis: interaction of rifampicin and vitamin K antagonists.

Authors:  Lars Mizera; Tobias Geisler; Klaus Mörike; Meinrad Gawaz; Martin Steeg
Journal:  BMJ Case Rep       Date:  2018-02-12

8.  Pharmacogenetics in clinical pediatrics: challenges and strategies.

Authors:  Sara L Van Driest; Tracy L McGregor
Journal:  Per Med       Date:  2013-09       Impact factor: 2.512

9.  Effect of VKORC1, CYP2C9, CFP4F2, and GGCX Gene Polymorphisms on Warfarin Dose in Japanese Pediatric Patients.

Authors:  Takuya Wakamiya; Tatsunori Hokosaki; Shin-Ichi Tsujimoto; Keisuke Kadota; Yusuke Nakano; Shigeo Watanabe; Mari Iwamoto; Masakatsu Yanagimachi; Shuichi Ito
Journal:  Mol Diagn Ther       Date:  2016-08       Impact factor: 4.074

Review 10.  Warfarin pharmacogenetics.

Authors:  Nita A Limdi; David L Veenstra
Journal:  Pharmacotherapy       Date:  2008-09       Impact factor: 4.705

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.